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Background: Mucin-1 (MUC1, CD227), more widely known as CA15-3, is an abundantly expressed epithelial cell
surface antigen and has evolved to be the most predictive serum tumour marker in breast cancer. PankoMab-GEX™,
which is currently being evaluated for its therapeutic efficacy in a phase IIb clinical trial, is a glyco-optimized
anti-MUC1 antibody specifically recognizing a tumour-associated MUC1 epitope (TA-MUC1). The current study
aimed to analyse the immunoreactivity of PankoMabGEX™ and its correlation with established clinico-pathological
variables including 10-year and overall survival in a large cohort of breast cancer patients.
Methods: Breast cancer tissue sections (n = 227) underwent a standardized immunohistochemical staining protocol
for TA-MUC1 by using PankoMab-GEX™ as a primary antibody. The staining was evaluated by two independent
observers and quantified by applying the IR-score.
Results: TA-MUC1 as detected by PankoMab-GEX™ was identified in 74.9% of breast cancer tissue sections. Patients
were subdivided according to the subcellular localisation of TA-MUC1 and cases classified as mem-PankoMab-GEX™
(solely membranous) positive, cyt-PankoMab-GEX™ (solely cytoplasmic) positive, double positive or as completely
negative were compared regarding their survival. Herein mem-PankoMab-GEX™-positive patients performed best, while
double-negative ones presented with a significantly shortened survival. Positivity for mem-PankoMab-GEX™ as well
as a double-negative immunophenotype turned out to be independent prognosticators for survival.
Conclusions: This is the first study to report on PankoMab-GEX™ in a large panel of breast cancer patients.
The PankoMab-GEX™ epitope TA-MUC1 could be identified in the majority of cases and was found to be an
independent prognosticator depending on its subcellular localisation. Since TA-MUC1 is known to be highly
immunogenic cancers staining positive for PankoMab-GEX™ might be more compromised by host anti-tumour
immune defence. Further, the observations reported here might be fundamental for selecting patients to undergo
PankoMab-GEX™-containing chemotherapy protocols.
Keywords: PankoMab-GEX™, Prognosis, Breast cancer, MUC1, TA-MUC1, Immunohistochemistry* Correspondence: sabine.heublein@med.uni-muenchen.de
1Department of Gynaecology and Obstetrics, Ludwig-Maximilians-University
of Munich, Marchioninistrasse 15, 81377 Munich, Germany
Full list of author information is available at the end of the article
© 2015 Heublein et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.




non NST 96 42.3
Grading


























Heublein et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:50 Page 2 of 8Background
Mucin-1 (MUC1, CD227), more widely known as CA15-
3, has evolved to be one of the best validated breast cancer
serum tumour markers [1]. In general, MUC1 is a trans-
membrane cell surface glycoprotein expressed by cells of
epithelial origin. Its extracellular domain is composed of a
variable number of repeats with multiple glycans attached
to the protein backbone. Although MUC1 is expressed on
both normal and cancerous cells, there exist significant
differences regarding glycosylation [2,3], expression level
[4] and subcellular localisation [5] comparing normal and
neoplastic cells.
PankoMab-GEX™ is a novel, meanwhile fully human-
ized and glyco-optimized anti-MUC1 antibody select-
ively recognizing a glyco-epitope termed TA-MUC1
(Tumour-Associated MUC1). TA-MUC1 has been char-
acterized as a carbohydrate-induced conformational epitope
[6,7]. Structure wise it comprises a PDTRP (Pro-Asp-Thr-
Arg-Pro) motif containing a specifically glyco-modified
threonine residue (T) [3,6-8]. Glycans linked to this threo-
nine by O-glycosylation are tumour specific carbohydrate
modifications themselves. Presence of this specifically
glyco-modified PDTRP motif is regarded to be an abso-
lute requirement for binding of PankoMab-GEX™ [6].
Scatchard plot analysis performed in breast cancer cell
lines revealed high binding affinity (up to KD = 7.1×10
−9 M)
and epitope density (up to 2.4×106 per cell) of the murine
IgG1, κ PankoMab antibody which is a precursor of the hu-
manized PankoMab-GEX™ [6]. TA-MUC1 has been identi-
fied to be predominantly expressed on cancer cells while
being virtually absent from the corresponding non-
malignant tissue. Cancer selectivity has been demon-
strated for a range of cancer entities including lung [9],
ovarian [4], cervical [10] or hepatocellular carcinoma [10].
To the best of our knowledge there are only few publica-
tions having studied TA-MUC1 in breast cancer tissue
and none of them included specific information on
PankoMab-GEX™ in healthy breast tissue [10-12].
In addition, PankoMab-GEX™ mediates antibody-
dependent cellular cytotoxicity (ADCC) [6], therefore
being anticipated to potentially evolve as an excellent
therapeutic antibody. Thus to further enhance its ADCC
activity glyco-optimization in proprietary human glyco-
engineered production cell lines (GlycoExpress™ platform)
was employed. Since PankoMab-GEX™ is internalized by
tumour cells in a temperature and time-dependent man-
ner, additional efforts have been undertaken to investigate
its potency in antigen-dependent toxin-mediated elimin-
ation of cancer cells [6]. Currently the unconjugated anti-
body is being evaluated for its therapeutic efficacy in a
double-blind, randomized, placebo-controlled phase IIb
clinical trial in ovarian cancer patients.
Some previous studies on the immunoreactivity of
PankoMab-GEX™ have been published [4,9,10,12,13]. Forinstance the murine PankoMab antibody was applied in a
lung cancer study [9] and in a study to discriminate sera
of patients suffering from benign versus malignant disease
of the ovary [13]. However evaluation of PankoMab-
GEX™ immunoreactivity as correlated to routine clinico-
pathological variables and survival in a large panel of
breast cancer patients is missing so far. Hence the present
study aimed to analyse PankoMab-GEX™ immunostaining
with regard to the aforementioned parameters.
Methods
Patients
Formalin-fixed, paraffin-embedded (FFPE) breast cancer
samples from 227 patients who underwent surgery due
to a malignant tumour of the breast at the Department
of Gynaecology and Obstetrics, Ludwig-Maximilians-
University of Munich, Germany were included in this
study (Table 1). Histopathological tumour subtypes were
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grading was determined according to the Elston and Ellis
criteria [14] by a gynecological pathologist (D.M.). Data
regarding hormone receptors (ER, PR, Her2), patient age
and overall survival were retrieved from patients’ charts or
from the Munich Cancer Registry, respectively. None of
the patients (n = 227) had a positive family history for
breast cancer. Mean patient age was 58.2 ± 13.3 years.
More than half of all patients were diagnosed for a breast
tumour smaller than 2 cm in size (n (pT1) = 153 (68.0%),
n (pT2) = 66 (29.3%), n (pT3) = 1 (0.4%), n (pT4) = 5
(2.2%)) and for cancer without lymph node metastasis
(pN0: 56.7%), with a significant number of cases also dis-
playing a DCIS/LCIS fraction within the invasive carcin-
omas. Mean overall survival was 12.2 years (95% CI: 11.6 -
12.8 years), mean follow-up was 9.8 years (95% CI: 9.29 -
10.4 years), and 49 deaths were documented. Further
patients’ characteristics are listed in Table 1. This study
has been performed and presented according to the RE-
MARK criteria [15].
Immunohistochemistry
Tissue samples were fixed in buffered formalin solution
(3.7%) immediately after resection and underwent stan-
dardized paraffin embedding. Slides were stained using
PankoMab-GEX™ (final concentration: 2 μg/ml in PBS)
as described before [4,11]. Human endometrium tissue
served as positive control for PankoMab-GEX™ stainingFigure 1 PankoMabGEX™ immunoreactivity in breast cancer tissue. Represen
GEX™ positive (B, E) and double-positive (C, F) cases were distinguished.
D-F, respectively.as described elsewhere [4], while replacement of the pri-
mary antibody with human IgG was performed as nega-
tive control.
PankoMab-GEX™ immunoreactivity was examined by
two independent observers by consensus. Samples were
assessed by applying an established semiquantivative im-
munoreactive score (IRS) [4,11,16]. The IR score quantifies
immunoreactivity by multiplication of staining intensity
(graded as 0 = no, 1 =weak, 2 =moderate, and 3 = strong
staining) and percentage of positively stained cells (0 = no
staining, 1 = ≤ 10% of the cells, 2 = 11–50% of the cells,
3 = 51–80% of the cells and 4 = ≥ 81% of the cells). A
Leitz (Wetzlar, Germany) microscope was employed,
and representative images were taken by a CCD colour
camera (JVC, Japan). In accordance with previously pub-
lished data, tissue samples with an IRS higher than 2 - re-
garding membranous PankoMab-GEX™ staining - were
scored as positive [17,18]. Since cytoplasmic PankoMab-
GEX™ staining was found to be quite low, the threshold
was set at an IR score of 0 with cases scored as IRS higher
than 0 counted as positive.
Statistics
The IBM statistic package SPSS (version 22) was used to
analyse the data for statistical significance. Microsoft
Excel as well as Microsoft PowerPoint were employed to
illustrate data. Fisher’s exact test was used to test nom-
inal data for independence. Survival data were comparedtative images of mem-PankoMab-GEX™ positive (A, D), cyt-PankoMab-
The scale bars in A and D equal 100 μm and apply to A-C and
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survival times were tested for significance by calculating
chi-square statistics of the log rank test. Multivariate
analysis was performed using the Cox-regression model.
Data were assumed to be statistically different in case of
p < 0.05.
Ethics statement
The tissue samples used were left over material after all
diagnostics had been completed and were retrieved from
the archive of Gynaecology and Obstetrics, Ludwig-
Maximilians-University, Munich, Germany. Patient data
were fully anonymised. The study was approved by the
Ethics Committee of the Ludwig-Maximilians-University,
and was performed according to the standards set in the
declaration of Helsinki 1975.Table 2 Distribution of PankoMabGEX™ staining patterns
Mem-PankoMabGEX Cyt-PankoMabGEX
Other Mem only Other Cyt on
n (%) n (%) p n (%) n (%
Histology
NST 79 (34.8) 52 (22.9) ns 122 (53.7) 9 (4
non NST 57 (25.1) 39 (17.2) 92 (40.5) 4 (1
Grading
G1. G2 59 (37.8) 44 (28.2) ns 98 (62.8) 5 (3
G3 34 (21.8 19 (12.2) 50 (32.1) 3 (1
pT
pT1 82 (36.4) 71 (31.6) 0.002 146 (64.9) 7 (3
pT2-pT4 54 (24.0) 18 (8.0) 66 (29.3) 6 (2
pN
pN0 62 (28.8) 60 (27.9) 0.001 114 (53.0) 8 (3
pN1-pN3 68 (31.6) 25 (11.6) 88 (40.9) 5 (2
CIS
no 65 (28.6) 42 (18.5) ns 102 (44.9) 5 (2
yes 71 (31.3) 49 (21.6) 112 (49.3) 8 (3
ER
negative 22 (10.7) 8 (3.9) ns 29 (14.1) 1 (0
positive 99 (48.3) 76 (37.1) 165 (80.5) 10 (4
PR
negative 43 (22.6) 19 (10.0) 0.028 59 (31.1) 3 (1
positive 66 (34.7) 62 (32.6) 121 (63.7) 7 (3
Her2
negative 90 (50.0) 70 (38.9) ns 150 (83.3) 10 (5
positive 16 (8.9) 4 (2.2) 18 (10.0) 2 (1
age
≤55 y 57 (25.2) 33 (14.6) ns 85 (37.6) 5 (2
>55 y 79 (35.0) 57 (25.2) 128 (56.6) 8 (3Results
The PankoMab-GEX™ epitope TA-MUC1 is related to
clinicopathological parameters
PankoMab-GEX™ staining was restricted to tumour cells,
whereas breast stroma remained negative (Figure 1).
TA-MUC1 as detected by PankoMab-GEX™ was identi-
fied in 74.9% (170/227) of breast cancer tissue sections.
Patients were then subdivided according to the subcellular
localisation of TA-MUC1. Solely membranous (mem-)
PankoMab-GEX™ positivity was observed in 40.1% (91/
227) of tissue samples, while exclusively cytoplasmic (cyt-)
PankoMab-GEX™ staining accounted for only 5.7% (13/
227). About one third of cancers (29.1%, 66/227) showed
both membranous and cytoplasmic staining (referred to as
‘double positive’) while 25.1% (57/227) of samples studied
did not stain at all (referred to as ‘double negative’).Double negative Double positive
ly No Yes No Yes
) p n (%) n (%) p n (%) n (%) p
.0) ns 107 (47.1) 24 (10.6) 0.008 85 (37.4) 46 (20.3) 0.026
.8) 63 (27.8) 33 (14.5) 76 (33.5) 20 (8.8)
.2) ns 79 (50.6) 24 (15.4) ns 73 (46.8) 30 (19.2) ns
.9) 38 (24.4) 15 (9.6) 37 (23.7) 16 (10.3)
.1) ns 116 (51.6) 37 (16.4) ns 115 (51.1) 38 (16.9) 0.041
.7) 52 (23.1) 20 (8.9) 44 (19.6) 28 (12.4)
.7) ns 96 (44.7) 26 (12.1) ns 94 (43.7) 28 (13.0) 0.011
.3) 67 (31.2) 26 (12.1) 56 (26.0) 37 (17.2)
.2) ns 78 (34.4) 29 (12.8) ns 76 (33.5) 31 (13.7) ns
.5) 92 (40.5) 28 (12.3) 85 (37.4) 35 (15.4)
.5) ns 17 (8.3) 13 (6.3) 0.008 22 (10.7) 8 (3.9) ns
.9) 141 (68.8) 34 (16.6) 120 (58.5) 55 (26.8)
.6) ns 42 (22.1) 20 (10.5) 0.041 42 (22.1) 20 (10.5) ns
.7) 105 (55.3) 23 (12.1) 92 (48.4) 36 (18.9)
.6) ns 119 (66.1) 41 (22.8) ns 121 (67.2) 39 (21.7) ns
.1) 14 (7.8) 6 (3.3) 12 (6.7) 8 (4.4)
.2) ns 59 (26.1) 31 (13.7) 0.012 69 (30.5) 21 (9.3) ns
.5) 110 (48.7) 26 (11.5) 91 (40.3) 45 (19.9)
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ated with tumour size (p = 0.002) and lymph node status
(p = 0.001), no such correlation was observed in case of
cytoplasmic staining. Neither membrane nor cytoplasmic
staining was associated with histological subtype, tumour
grade, or with the presence of a DCIS/LCIS component,
respectively (Table 2). Further, TA-MUC1 as detected by
PankoMab-GEX™ was analysed in respect to hormone re-
ceptor and Her2 positivity. Progesterone receptor (PR)
positive cancers showed mem-PankoMab-GEX™ staining
more often than those being PR negative (p = 0.028). An
adverse association of borderline significance was seen in
case of mem-PankoMab-GEX™ and Her2 positivity (p =
0.053). Cyt-PankoMab-GEX™ was not associated with ei-
ther hormone receptor or Her2 positivity. Cancer tissues
which were negative for TA-MUC1 at all were signifi-
cantly less often found to be of NST histology (p = 0.008)
and to show less ER (p = 0.008) or PR (p = 0.041). On the
other hand, double positive cases revealed significantly
more frequently to be of NST histology (p = 0.026), to beFigure 2 PankoMabGEX™ predicts overall survival in breast cancer. Univaria
of the four subgroups (mem-PankoMab-GEX™ positive, cyt-PankoMab-GEX™
mem-PankoMab-GEX™ positivity turned out to be related to more favourab
associated with worse prognosis (D). Neither cyt-PankoMab-GEX™ positivity
overall survival. The term “remaining cases” refers to the three immunophelarger in tumour size (p = 0.041) and to be lymph node
positive (p = 0.011).
PankoMab-GEX™ is an independent prognostic marker in
breast cancer patients
The several groups of cases were analysed regarding their
ten year and overall survival. Patients classified as positive
for mem-PankoMab-GEX™ presented with a significantly
more favourable survival than those diagnosed for other
staining locations (Figure 2A; Additional file 1: Figure
S1A). Similarly, mem-PankoMab-GEX™ positive cases
indicated better survival compared the group of
remaining (i.e. cyt-PankoMab-GEX™ positive, double
negative and double positive) cases (overall survival: p =
0.002, Figure 2B; 10-year survival: p < 0.001, Additional
file 1: Figure S1B). In cases where TA-MUC1 was not
expressed at all (double-negative) the overall survival rates
(p = 0.003, Figure 2D) as well as the 10-year (p = 0.002,
Additional file 1: Figure S1D) were found to be signifi-
cantly reduced compared to the remaining cases. Finally,te analysis revealed significant differences regarding overall survival
positive, double negative and double positive) studied (A).
le (B) survival, while a double negative immunophenotype was
(C) nor a double positive immunophenotype (E) was predictive for
notypes different from the one indicated in the respective graph (B-E).
Table 3 Absence of PankoMabGEX™ staining is an independent prognosticator for reduced 10-year survival
10-year survival
95% CI
Covariate Coefficient (bi) [HR Exp (bi)] Lower Upper P-value
Histology (NST vs. other) −0.94 0.39 0.09 1.71 ns
Grading (G1. G2 vs. G3) −0.39 0.68 0.19 2.47 ns
pT (pT1 vs. pT2-pT4) −0.03 0.97 0.34 2.80 ns
pN (pN0 vs. pN1-pN3) 0.68 1.98 0.64 6.11 ns
CIS (fraction within the invasive carcinoma) (no vs. yes) 0.05 1.05 0.39 2.85 ns
ER (neg. vs. pos.) −1.20 0.30 0.06 1.42 ns
PR (neg. vs. pos.) 0.26 1.30 0.37 4.62 ns
Her2 (neg. vs. pos.) 1.45 4.25 1.07 16.94 0.040
age (≤55y vs. > 55 y.) 0.74 2.09 0.69 6.31 ns
PankoMabGEX™ double negative (no vs. yes) 1.30 3.67 1.12 12.08 0.032
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rates of cyt-PankoMab-GEX™ positive or double-positive
patients were contrasted to the remaining cases, respect-
ively (Figure 2C, E; Additional file 1: Figure S1C, E).
Multivariate Cox-Regression analysis was performed
in order to test whether mem-PankoMab-GEX™ staining
or the total absence of PankoMab-GEX™ staining (‘double-
negative group’) might be prognosticators of 10-year or
overall survival. Besides Her2-positivity, the diagnosis of
being double-negative for the PankoMab-GEX™ turned out
to be an independent negative prognosticator for 10-year
survival (Table 3), though both failed to be of prognostic
significance regarding multivariate analysis of overall sur-
vival rates. More importantly, the mem-PankoMab-GEX™
immunophenotype proved to be an independent posi-
tive predictor for 10-year (p = 0.022) as well as overall
(p = 0.042) survival. ER positivity as well as a positive
lymph node status was a further independent predictor







Histology (NST vs. other) −0.49 0.61
Grading (G1. G2 vs. G3) −0.51 0.60
pT (pT1 vs. pT2-pT4) −0.17 0.84
pN (pN0 vs. pN1-pN3) 0.61 1.84
CIS (fraction within the invasive carcinoma) (no vs. yes) 0.08 1.08
ER (neg. vs. pos.) −1.53 0.22
PR (neg. vs. pos.) 0.10 1.10
Her2 (neg. vs. pos.) 0.92 2.52




Since subcellular localisation of certain MUC1 isoforms
has been associated with tumour cell aggressiveness and
cancer prognosis [19-21], this relationship was also stud-
ied using the antibody PankoMab-GEX™, which detects
a tumour-associated epitope of MUC1 (TA-MUC1) [6].
Our study revealed that exclusive membrane-associated
TA-MUC1 staining (measured as mem-PankoMab-GEX™)
was inversely correlated with tumour size (pT stage) and
lymph node metastasis (pN stage). However, since more
than half of all samples were classified as pT1 the associ-
ation of mem-PankoMab-GEX™ and pT-stage might partly
be biased by sampling. In line with Vegt et al. [22] the ab-
sence of both membranous and cytoplasmic TA-MUC1
(‘double negative’ immunophenotype) was often found
in tumours characterized as hormone receptor-negative.
MUC1 has been shown to interact with hormone receptors
e.g. by stabilizing ER and by stimulating ER-mediated tran-
scription [23], hereby indicating a functional interaction ofgnosticator for advanced 10-year and overall survival
Overall survival










0.16 2.38 ns −0.31 0.73 0.23 2.34 ns
0.18 1.97 ns −0.59 0.55 0.19 1.63 ns
0.30 2.36 ns −0.06 0.94 0.39 2.26 ns
0.63 5.40 ns 1.06 2.89 1.11 7.53 .030
0.40 2.97 ns 0.28 1.32 0.57 3.06 ns
0.05 0.94 .041 −1.66 0.19 0.05 0.80 .023
0.28 4.28 ns 0.37 1.45 0.43 4.91 ns
0.56 11.35 ns 0.67 1.95 0.46 8.20 ns
0.71 6.30 ns 0.28 1.32 0.55 3.18 ns
0.01 0.70 .022 −1.21 0.30 0.09 0.96 .042
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Nevertheless, concordant blockage of MUC1 and ER has
failed to be effective in a randomized phase II trial per-
formed with locally advanced, metastasized breast cancer
[24]. The current study detected some relations of TA-
MUC1 staining and hormone receptors, too. Presence of
mem-PankoMab-GEX™ was associated with PR positivity.
Further, staining of mem-PankoMab-GEX™ showed a trend
of being negatively associated with Her2 positivity. With
Her2 being known to indicate poor prognosis in breast
cancer [25-27] and with mem-PankoMab-GEX™ staining
predicting just the opposite an adverse relationship of both
markers was expected.
More importantly, the current study reports a positive
correlation of membrane-associated TA-MUC1 with pro-
longed survival. On the opposite, cases in which staining
with PankoMab-GEX™ was also seen in the cytoplasm, or
was absent at all, presented with shorter survival periods.
Studies with other anti-MUC1 antibodies obtained similar
results regarding apical expression of MUC1 and its
correlation with better overall survival [20,22] and low
metastatic potential [19]. Cytosolic localisation of MUC1,
on the other hand, has been found to be elevated in breast
cancer [28] and to protect pancreatic cancer cells from
undergoing apoptosis [29].
A similar association of PankoMab-GEX™ expression
and prognosis has previously been reported in unifocal
breast cancer [12] and in lymph node-positive lung cancer
[9]. Two effects may contribute to the improved survival
of patients with exclusively membranous expression of
TA-MUC1. First, membranous localisation of MUC1 - as
opposed to cytoplasmic localisation or total loss of expres-
sion - is an indicator of a more differentiated tumour. Sec-
ond, modified MUC1, as long as it is exposed at the cell
membrane, is immunogenic. MUC1 is known to induce
autoantibody formation in cancer patients [30-32]. The
TA-MUC1 epitope recognized by PankoMab-GEX™ is an
immunodominant antigenic region of MUC1 representing
a mixed peptide-carbohydrate conformational epitope [6]
that involves either of two carbohydrate structures termed
TF (Thomsen-Friedenreich antigen) or Tn (TF precursor)
[33]. We thus hypothesize that breast cancer cells
displaying mem-PankoMab-GEX™ positivity are predis-
posed to be recognized by endogenous or newly induced
anti-MUC1 auto-antibodies potentially acting via ADCC
mechanisms, as demonstrated for PankoMab-GEX™ [6].
Finally, our observations reported here may also be funda-
mental for selecting patients to undergo PankoMab-
GEX™-containing chemotherapy protocols.
Conclusions
In conclusion, this study highlighted the TA-MUC1 epitope
as detected by PankoMab-GEX™ to be widely expressed in
a large body of breast cancer tissue samples, and - in caseof its membrane-restricted expression - to be an inde-
pendent predictor for better survival. Hence our results
demonstrate that PankoMab-GEX™, which has been de-
veloped primarily as a therapeutic antibody, may also
serve as a diagnostic tool.
Additional file
Additional file 1: Figure S1. PankoMabGEX™ predicts 10-year survival
in breast cancer. Univariate analysis revealed significant differences
regarding 10-year survival of the four subgroups (mem-PankoMab-GEX™
positive, cyt-PankoMab-GEX™ positive, double negative and double
positive) studied (A). mem-PankoMab-GEX™ positivity turned out to
be related to more favourable (B) survival, while a double negative
immunophenotype was associated with worse prognosis (D). Neither
cyt-PankoMab-GEX™ positivity (C) nor a double positive immunophenotype
(E) was predictive for 10-year survival. The term “remaining cases” refers to
the three immunophenotypes different from the one indicated in the
respective graph (B-E).
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